KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pfizer (PFE) Gross Margin (2016 - 2026)

Pfizer has reported Gross Margin over the past 18 years, most recently at 51.69% for Q1 2026.

  • Quarterly Gross Margin fell 1705.0% to 51.69% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 31.46% through Mar 2026, down 2040.0% year-over-year, with the annual reading at 74.33% for FY2025, 18714.0% up from the prior year.
  • Gross Margin was 51.69% for Q1 2026 at Pfizer, down from 69.97% in the prior quarter.
  • Over five years, Gross Margin peaked at 77.29% in Q1 2024 and troughed at 1090.72% in Q3 2024.
  • The 5-year median for Gross Margin is 34.64% (2025), against an average of 100.7%.
  • Year-over-year, Gross Margin tumbled -62726bps in 2024 and then surged 100917bps in 2025.
  • A 5-year view of Gross Margin shows it stood at 73.22% in 2022, then plummeted by -264bps to 120.24% in 2023, then plummeted by -807bps to 1090.72% in 2024, then skyrocketed by 106bps to 69.97% in 2025, then plummeted by -174bps to 51.69% in 2026.
  • Per Business Quant, the three most recent readings for PFE's Gross Margin are 51.69% (Q1 2026), 69.97% (Q4 2025), and 81.55% (Q3 2025).